Early Stage Biomarkers Screening of Prostate Cancer Based on Weighted Gene Coexpression Network Analysis

Meng, Lingyin; Yang, Li; Ren, Jing; Shi, Tao; Men, Jianlong; Chang, Chawnshang

doi:10.1089/dna.2018.4406

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another previously established up-regulated marker we unearthed was glutathione peroxidase (GPX3), an extracellular selenoprotein member known to play important roles in oxidative stress-induced apoptosis [58]. More recently, the overexpression of GPX3 has been reported in prostate cancer, gastric cancer, CRC pathogenesis and leukaemia stem cells [59–61]. Furthermore, Barett et al, had previously demonstrated that elevated plasma GPX3 may serve protective roles in inflammation-associated colon carcinogenesis by reducing oxidative DNA damage [32].…”

Section: Discussionmentioning

confidence: 99%

Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel

et al. 2019

View full text Add to dashboard Cite

Background: One of the most significant challenges in colorectal cancer (CRC) management is the use of compliant early stage population-based diagnostic tests as adjuncts to confirmatory colonoscopy. Despite the near curative nature of early clinical stage surgical resection, mortality remains unacceptably high-as the majority of patients diagnosed by faecal haemoglobin followed by colonoscopy occur at latter stages. Additionally, current populationbased screens reliant on fecal occult blood test (FOBT) have low compliance (~ 40%) and tests suffer low sensitivities. Therefore, blood-based diagnostic tests offer survival benefits from their higher compliance (≥ 97%), if they can at least match the sensitivity and specificity of FOBTs. However, discovery of low abundance plasma biomarkers is difficult due to occupancy of a high percentage of proteomic discovery space by many high abundance plasma proteins (e.g., human serum albumin). Methods: A combination of high abundance protein ultradepletion (e.g., MARS-14 and an in-house IgY depletion columns) strategies, extensive peptide fractionation methods (SCX, SAX, High pH and SEC) and SWATH-MS were utilized to uncover protein biomarkers from a cohort of 100 plasma samples (i.e., pools of 20 healthy and 20 stages I-IV CRC plasmas). The differentially expressed proteins were analyzed using ANOVA and pairwise t-tests (p < 0.05; fold-change > 1.5), and further examined with a neural network classification method using in silico augmented 5000 patient datasets. Results: Ultradepletion combined with peptide fractionation allowed for the identification of a total of 513 plasma proteins, 8 of which had not been previously reported in human plasma (based on PeptideAtlas database). SWATH-MS analysis revealed 37 protein biomarker candidates that exhibited differential expression across CRC stages compared to healthy controls. Of those, 7 candidates (CST3, GPX3, CFD, MRC1, COMP, PON1 and ADAMDEC1) were validated using Western blotting and/or ELISA. The neural network classification narrowed down candidate biomarkers to 5 proteins (SAA2, APCS, APOA4, F2 and AMBP) that had maintained accuracy which could discern early (I/II) from late (III/IV) stage CRC. Conclusion: MS-based proteomics in combination with ultradepletion strategies have an immense potential of identifying diagnostic protein biosignature.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel

et al. 2019

View full text Add to dashboard Cite

show abstract

Structural model for formation of packages of clinical and diagnostic tests to organize personalized medical care for patients with malignant tumors of the prostate gland

Andreev

Анатольевич²,

Завьялов

et al. 2021

Medical Journal of the Russian Federation

View full text Add to dashboard Cite

BACKGROUND: Prostate carcinoma is a serious social and economic problem; it ranks second among the most frequently diagnosed malignant tumors worldwide and it ranks sixth in the structure of causes of death from cancer in men. The correct organization of prevention and screening as well as the use of the latest methods of clinical instrumental and molecular analysis at all stages of treatment and diagnostic process can fundamentally improve the outcomes of the disease. AIM: This study aimed to analyze of the best international experience in the development of basic clinical and instrumental test packages that determine the personalized choice of medical prescriptions for the treatment and diagnostic process of prostate cancer. METHODS: The study included papers published after January 1, 2008, with an emphasis on the analysis of results posted in the last 2 years in the PubMed/Medline electronic database as reliable sources of information. RESULTS AND DISCUSSION: This study explored the basic structural model of the formation of clinical and diagnostic packages at the implementation of a personalized treatment and diagnostic process in prostate cancer. The main biomarkers of prostate cancer used in clinical practice have been identified, and the informative value of the newest biomarker tests has been established. Diagnostic tools that are ready for wider implementation in oncological practice are predictive models, such as the 4K algorithm, Score, SelectMDx, Stockholm-3 model, justifying the need to perform a prostate biopsy in a particular patient. Some promising biomarker characteristics of prostate cancer, assessed at the nonclinical, experimental stage, have been demonstrated. CONCLUSIONS: This study found that (1) Revision of the algorithms for personalized treatment is becoming an important element in the provision of patient-oriented cancer care. (2) Periodic reassessment of the individual portrait of the tumor process is necessary for the correct organization of treatment and diagnostic measures in a particular patient. (3) Finally, for the implementation of the whole range of possibilities of individual treatment, close interaction with the representatives of various medical specialties in the framework of the implementation of translational medicine programs in oncologyis important.

show abstract

Early Stage Biomarkers Screening of Prostate Cancer Based on Weighted Gene Coexpression Network Analysis

Cited by 2 publications

References 29 publications

Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel

Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel

Structural model for formation of packages of clinical and diagnostic tests to organize personalized medical care for patients with malignant tumors of the prostate gland

Contact Info

Product

Resources

About